Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.
Keith Allen

Dr. Keith Allen MD

Director, Cardiothoracic Vascular Surgery Research, Mid America Heart & Lung Surgeons, PC

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Keith Allen, MD, is a Director of Cardiothoracic-Vascular Surgery Research at the Mid America Heart Institute in Kansas City, Missouri. He is board certified in Thoracic, Vascular, and General Surgery. Dr. Allen maintains an active clinical research department and has over 100 publications in journals such as the NEJM, JTCVS, and The Annals of Thoracic Surgery. He is serving on the FDA's Circulatory Device Panel. Additionally, Dr. Allen continues to advise companies on clinical study design, Medicare reimbursement issues, and FDA regulatory process including two successful PMA presentations to the FDA device panel as the lead presenter. He is a Fellow of the American College of Surgeons and a member of American Association of Thoracic Surgeons (AATS), Society of Thoracic Surgery (STS), and the International Society for Minimally Invasive Surgery (ISMICS). (This is me - Update Profile)


Employment History

2007 - Unspecified
Director, Cardiothoracic Vascular Surgery Research, Mid America Heart & Lung Surgeons, PC
1994 - 2007
Surgeon, CORVASC MD'S PC

GLG NewsSM Analyses by Keith Allen(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Drug Eluting Stents:The Next Vioxx

December 14, 2006

Trading restenosis for Thrombosis? New questions about drug-eluding stents. | content.nejm.org

1. DES whether used on or off label will likely require life long anticoagulation with Plavix like drugs.

2. The incidence of late thrombosis is significant when anticoagulation is interrupted for events such as elective surgery.

3. Unlike restenosis following insertion of a bare metal stent which rarely results in death to the patient, late thrombosis following use of a DES results in a 50% mortality.

4.  Hints of this problem were present during FDA presentations prior to DES approval which may lead to significant liability as this problem becomes more apparent.

Leading institutions connect with Keith Allen through GLG

GLG Live Meetings with Keith Allen(?)

Keith Allen has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare